FY2025 · ended Dec 31, 2025 · Revenue $0, -100.0% YoY · Filed Mar 25, 2026
Kiora Pharmaceuticals, Inc. (KPRX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $0 and a net loss of $10.8 million. Free cash flow was -$10.1 million. As of Jun 30, 2026 it held $16.8 million in cash and investments and $333,022 in total debt.
Revenue
$0
-100.0% vs prior year
Net income
$-10.84M
-401.4% vs prior year
Operating cash flow (TTM)
$-8.51M
-8.5% vs year-ago TTM
Free cash flow (TTM)
$-8.61M
-9.7% vs year-ago TTM
EPS
$-2.64
-403.4% vs prior year
Dividend per share
None
Shares outstanding
3.95M
+31.7% vs prior year
Net cash
$16.51M
as of Jun 30, 2026
Operating margin
28.2%
FY 2024
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- KPRX (Nasdaq), KPHMW (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Encinitas, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1372514
- Former names
- EYEGATE PHARMACEUTICALS INC (until Nov 4, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2021 Dec 31, 2021 |
FY 2020 Dec 31, 2020 |
FY 2019 Dec 31, 2019 |
|---|---|---|---|---|---|
| Revenue | $0 | $16.0M | $0 | $12,059 | $2.7M |
| Operating income | -$12.8M | $4.5M | -$14.2M | — | — |
| Net income | -$10.8M | $3.6M | -$13.8M | -$6.9M | -$7.1M |
| Diluted EPS | -$2.64 | $0.87 | -$57.12 | — | — |
| Operating cash flow | -$10.0M | $8.6M | -$10.7M | -$7.3M | -$8.2M |
| Free cash flow | -$10.1M | $8.6M | -$10.7M | -$7.3M | — |
| Total assets | $24.3M | $36.5M | $20.1M | $15.3M | $10.1M |
| Total liabilities | $8.1M | $10.7M | $5.6M | $5.6M | $3.5M |
| Stockholders' equity | $16.1M | $25.8M | $14.6M | $9.7M | $6.6M |
| Cash and investments | $17.1M | $26.8M | $7.9M | $1.2M | $3.8M |
| Total debt | $368,259 | $57,170 | $209,411 | $363,935 | $83,926 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Oct 29, 2026 | Oct 23, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 8, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Aug 19, 2026 | Aug 19, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2026 | Aug 7, 2026 |
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 18, 2026 | Jun 18, 2026 |
All 926 Kiora Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.